Danaher reports strong Q1 revenue, exceeding estimates, with high growth in bioprocessing and diagnostics
From Stock Story: 2025-04-22 21:35:00
Danaher (NYSE:DHR) reported Q1 CY2025 revenue of $5.74 billion, beating analyst estimates. Non-GAAP profit per share was $1.88. Q2 revenue guidance is $5.92 billion, above estimates. CEO credits recurring revenue and diversified markets for stable performance. The bioprocessing segment showed strong growth, while diagnostics exceeded expectations. Danaher plans to mitigate tariff impacts and focus on M&A. Q2 and full-year outlook anticipates low-single digit revenue growth. Analysts question bioprocessing growth, tariff impact, and margin sustainability. StockStory will monitor order growth, tariff mitigation, and market trends. For top market-beating stocks, check out StockStory’s curated list.
In Q1 CY2025, Danaher (NYSE:DHR) reported revenue of $5.74 billion, surpassing analyst estimates. Non-GAAP profit per share was $1.88. Q2 revenue guidance is $5.92 billion. CEO credits recurring revenue and diversified markets for stable performance. Bioprocessing had high-single digit growth, while diagnostics exceeded expectations. Danaher plans to mitigate tariff impacts and focus on M&A. Q2 and full-year outlook anticipates low-single digit revenue growth. Analysts question bioprocessing growth, tariff impact, and margin sustainability. StockStory will monitor order growth, tariff mitigation, and market trends. For top market-beating stocks, check out StockStory’s curated list.
Read more at Stock Story: Bioprocessing Momentum and Tariff Strategy Drive Guidance Above Expectations